Cancer Cells Restrict Necessary Cell Division

Targeted therapeutics is a type of cancer treatment that uses drugs to precisely 'target' cancer cells without affecting normal cells. Although targeted therapy is an effective treatment, many individuals prefer to use it in combination with other therapies such as traditional or standard chemotherapy, surgery, or radiation therapy. Developments in research for DNA changes and proteins that drive cancer are proving effective to design promising treatments that target such proteins. For different types of cancers come different types of drugs that individually target distinct cancer. However, tumors are tested to check the target, and provide therapy if the drugs are available. As traditional chemotherapy can damage normal cells while killing cancer cells, the targeted therapeutics market is expected to witness growth during the forecast period.

Targeted therapy varies in types with the primary objective to help treat cancer by intervening with particular proteins that help tumors develop and circulate throughout the body. The human body functions with the immune system constantly working to find the problems and fight. However, cancer cells can hide from the immune system making it difficult to kill. Specific targeted therapy can mark the cancer cells to make it easier for the immune system to target and destroy them. Some targeted therapies can help in boosting the immune system so it works efficiently against cancer. Furthermore, human body cells divide themselves when needed. Cells receive signals that attach to proteins on the cell surface, indicating cells to divide. Thus, a body recreates the cells continuously depending on the body requirements. However, cancer cells can make changes in proteins, which can restrict cell division, affecting the body. Types of targeted therapy interfere with the proteins that prevent the cell division process. This process helps to slow down the cancer growth in the body. With an increasing number of cancer patients across the world, the global targeted therapeutics market is likely to grow during the forecast period.

To know the scope of our report Get a Sample on Targeted Therapeutics Market

Lack of Availability of Resources, Patient Care During COVID-19 Pandemic Affecting Cancer Treatment

The COVID-19 pandemic has hit healthcare services in multiple dimensions. The healthcare industry is witnessing several obstacles varying from suspending the routine patient flow to healthcare equipment. Moreover, overwhelming healthcare supplies, implementation of extra emergency measures, and social distancing with expanded utilization of tele-health and virtual medicine are some of the common situations across most healthcare facilities. As a prudent approach, oncology applications implemented explicit measures such as decreasing the number of patients in outpatient dispensaries, reducing redundant or elective procedures, and discharging patients from inpatient services. All the factors are contributing to the slowdown of the healthcare industry and hindering the expansion of the targeted therapeutics market to a certain extent.

The COVID-19 pandemic has detrimentally impacted cancer care across the world. Patients with cancer are defenseless people predisposed to many harms during crisis and virus pandemics, including susceptivity to life-threatening viruses and suspension of their cancer or usual medical care. Oncologists across the globe are facing major challenges to provide high-quality constant unfragmented cancer treatment while reducing a patient's risk to exposure during care. The pandemic is likely to affect more in nations with low or developing economy resulting in inadequate resources, sparse infrastructure, deficiency of healthcare providers and coordinated care teams, deficiency of medical equipment and personal protective equipment (PPE), and poor access to technology. Thus, the COVID-19 is likely to leave a mark on the global targeted therapeutics market post-pandemic.

Get a glimpse of the in-depth analysis through our Report Brochure

Growing Number of Cancer Patients Requires Advanced Treatment Therapies

The International Agency for Research on Cancer (IARC) has estimated more than 19 million cancer patients in 2020. Nearly 10 million of those patients have died from cancer-related conditions. The number of cancer patients is expected to tremendously increase, reaching more than 27 million new cancer cases by 2040. Healthcare industry and governing organizations are constantly taking measures and investing more in cancer treatment and drugs to avoid such casualties. Targeted therapy is proving to be an efficient potential treatment with promising therapeutic outcomes across a broad range of cancers. High pervasiveness and growing number of cancer patients across the world are predicted to advance the growth of the global targeted therapeutics market during the forecast period. Thus, the global targeted therapeutics market is anticipated to expand at a CAGR of ~2% from 2021 to 2031.

Variety of Techniques to Treat Cancer Relieves Stress of Recovering Patients

The progress in biotechnology allowed the synthesis of certain biological molecules in microorganisms and other existing cells utilizing the recombinant DNA technology. The world of biologics has grown to encompass a broad range of products. The increase in investment and continues innovative approaches for cancer treatments have led to the rise of biologics in recent years. In addition, some of the targeted therapeutics monoclonal antibodies come in the world's best-selling drugs. On the other hand, small molecule drugs that can enter cells readily due to their low molecular weight are proving efficient to affect other molecules, such as proteins and may cause cancer cells to die. The small-molecule drugs and therapeutic proteins vary considerably in many of their class properties. However, different physicochemical properties not only affect the pharmacological aspects, but also the reliability, efficiency, and manufacturing quality of the drugs.

Compared to monoclonal antibodies, small molecule drugs are relatively uncomplicated synthetic compounds and can be produced by chemical synthesis. The pharmacological exercise, balance, and permeability of small molecules mainly depend on chemistry as opposed to fundamental synergies. Due to their attributes, small-molecule drugs can be determined in a variety of ways, including orally. Their oral bioavailability is certainly a distinct advantage over biologics in drug reinforcement. The growing popularity of various techniques in the targeted therapeutics market is influencing healthcare administrations and patients toward it, and is expected to increase in demand during the forecast period.

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Targeted therapy comprises drugs that obstruct increase and proliferation of cancer by interfering with particular molecules that are involved in the expansion of carcinogenic cells. The world is expected to witness increasing incidences of cancers such as breast cancer, lung cancer, colorectal cancer, and gastrointestinal cancer, among others, thus boosting the global targeted therapeutics market. However high expenses of these drugs, along with increased cost of molecular diagnostic tests to detect cancer are anticipated to hamper the growth of the targeted therapeutics market. Nevertheless, increasing investments in cancer research, improving insurance coverage, and rising number of new targeted anti cancer drugs are projected to overcome all the restraints of the targeted therapeutics market during the forecast period.

Targeted Therapeutics Market: Overview

  • According to Transparency Market Research’s latest report on the global targeted therapeutics market for the historical period of 20172019 and forecast period of 20212031, increase in incidence of cancer across the globe, surge in global geriatric population, and rise in product approvals are projected to drive the global targeted therapeutics market during the forecast period
  • According to the report, the global targeted therapeutics market was valued over US$ 67.8 Bn in 2020 and is anticipated to expand at a CAGR of ~2% from 2021 to 2031

Increase in Product Approvals Globally: Key Drivers

  • Increase in the number of product approvals for the treatment of different types of cancer, along with robust pipeline products in early and late phases of clinical trials is expected to augment the global targeted therapeutics market during the forecast period
  • For instance, in March 2020, Sanofi’s Sarclisa was approved in combination with pomalidomide and dexamethasone in the U.S. for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and by the European Commission in June 2020. Sarclisa has presently been launched in the U.S., Austria, Japan, Switzerland, Canada, and the U.K.
  • Novartis’s Kisqali (ribociclib) data demonstrates consistent efficacy benefit with Kisqali plus endocrine therapy across the primary intrinsic subtypes of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer
  • Rise in demand for the treatment leads to expansion of product pipeline and increase in product approvals, which in turn drives the global targeted therapeutics market

Promising Pipeline of Anticancer Drugs to Boost Market

  • Robust R&D studies are underway for the development of new drugs and therapies for cancer. Several products of different companies are in different phases of clinical trials and will be available in the market during the forecast period.
  • According to the Pharmaceutical Research and Manufacturers of America (PhRMA), around 836 drugs and vaccines were in different clinical stages for cancer in 2016
  • For instance, Pfizer’s Crizotinib, an oral inhibitor of the ALK gene that is mutated in about 5% of patients with NSCLC, produced unprecedented response rates in a phase 2 study
  • Other market players have developed target therapies for cancer that are in different clinical phases. These developments are likely to propel the global targeted therapeutics market during the forecast period.

High Cost of Treatment to Hamper Global Market

  • Targeted therapies that aim at specific genetic biomarkers have been widely adopted in the treatment of several cancer types
  • Tyrosine kinase inhibitors have become standard first-line therapy for patients with advanced NSCLC harboring EGFR mutations or ALK-gene rearrangements; however, these are expensive medications, costing thousands of dollars per month
  • In 2019, J&J mentioned in an article that Janssen’s Balversa (erdafitinib) was the first FGFR inhibitor approved by the FDA. This drug costs around US$ 10,080 to US$ 22,680 for a 28-day supply.
  • Hence, high cost of targeted therapy is likely to hamper the growth of the global targeted therapeutics market during the forecast period

Targeted Therapeutics Market: Competition Landscape

  • This report profiles major players in the global targeted therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global targeted therapeutics market is highly consolidated, with small number of players holding majority share
  • Leading players operating in the global targeted therapeutics market include
    • Amgen, Inc.
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Bayer AG, Merck & Co., Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • Merck KGaA
    • Sanofi
    • Seagen, Inc.
    • Takeda Pharmaceutical Company Limited
    • Pfizer, Inc.

Targeted Therapeutics Market: Key Developments

  • Key players in the global targeted therapeutics market are engaged in new product launches, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the global targeted therapeutics market. A few expansion strategies adopted by players operating in the global targeted therapeutics market include:
    • In March 2021, Amgen and Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, announced an agreement under which Amgen will acquire Five Prime Therapeutics for US$ 38.00 per share in cash, representing an equity value of approximately US$ 1.9 Bn. This acquisition adds Five Prime's innovative pipeline to Amgen's leading oncology portfolio.
    • In September 2020, Sanofi acquired Principia Biopharma, Inc. for US$ 3.68 Bn (EUR 3.2 Bn). This acquisition will strengthen the core areas of autoimmune and allergic diseases, giving Sanofi full control of tolebrutinib (SAR442168), as well as additional BTK inhibitors to develop further.
  • The report on the global targeted therapeutics market discussed individual strategies, followed by company profiles of manufacturers of targeted therapeutics. The competition landscape section has been included in the report to provide readers with a dashboard view of key players operating in the global targeted therapeutics market.

Targeted Therapeutics Market - Segmentation

Type
  • Monoclonal Antibodies
    • Angiogenesis Inhibitors
    • HER-2 Targeted Agents
    • Anti-CD20 Monoclonal Antibodies
  • Small Molecule
    • Tyrosine Kinase Inhibitors
      • mTOR Inhibitors
      • PARP Inhibitors
Application
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Multiple Sclerosis
  • Renal Cancer
  • Wet Age-related Macular Degeneration
  • Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer)
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

Targeted therapeutics market was valued over US$ 67.8 Bn in 2020 and to reach valuation of ~US$ 87 bn by 2031

Targeted therapeutics market is anticipated to expand at a CAGR of ~2% from 2021 to 2031

Targeted therapeutics market is driven by increase in the number of product approvals for the treatment of different types of cancer, along with robust pipeline products in early and late phases of clinical trials

North America dominated the global targeted therapeutics market, followed by Europe, and the trend is anticipated to continue during the forecast period

Key players operating in the global targeted therapeutics market include Amgen, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Bayer AG, Merck & Co., Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Targeted Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Targeted Therapeutics Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Cancer Prevalence and Incidence Rate by Key Region

    5.2. Clinical Trial Pipeline Analysis

    5.3. Key Industry Events

    5.4. COVID-19 Pandemics Impact on Global Targeted Therapeutics Market

6. Global Targeted Therapeutics Market Analysis and Forecast, by Type 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

        6.3.1. Monoclonal Antibodies

            6.3.1.1. Angiogenesis Inhibitors

            6.3.1.2. HER-2 Targeted Agents

            6.3.1.3. Anti-CD20 Monoclonal Antibodies

        6.3.2. Small Molecule

            6.3.2.1. Tyrosine Kinase Inhibitors

            6.3.2.2. mTOR Inhibitors

            6.3.2.3. PARP Inhibitors

    6.4. Global Targeted Therapeutics Market Attractiveness Analysis, by Type 

7. Global Targeted Therapeutics Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031

        7.3.1. Breast Cancer

        7.3.2. Colorectal Cancer

        7.3.3. Leukemia

        7.3.4. Lung Cancer

        7.3.5. Lymphoma

        7.3.6. Multiple Sclerosis

        7.3.7. Renal Cancer

        7.3.8. Wet Age-related Macular Degeneration

        7.3.9. Others

    7.4. Global Targeted Therapeutics Market Attractiveness Analysis, by Application 

8. Global Targeted Therapeutics Market Analysis and Forecast, by Distribution Channel 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Global Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel 

9. Global Targeted Therapeutics Market Analysis and Forecast, by Region 

    9.1. Key Findings

    9.2. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific

        9.2.4. Latin America 

        9.2.5. Middle East & Africa

    9.3. Global Targeted Therapeutics Market Attractiveness Analysis, by Region

10. North America Targeted Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

        10.2.1. Monoclonal Antibodies

            10.2.1.1. Angiogenesis Inhibitors

            10.2.1.2. HER-2 Targeted Agents

            10.2.1.3. Anti-CD20 Monoclonal Antibodies

        10.2.2. Small Molecule

            10.2.2.1. Tyrosine Kinase Inhibitors

            10.2.2.2. mTOR Inhibitors

            10.2.2.3. PARP Inhibitors

    10.3. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031

        10.3.1. Breast Cancer

        10.3.2. Colorectal Cancer

        10.3.3. Leukemia

        10.3.4. Lung Cancer

        10.3.5. Lymphoma

        10.3.6. Multiple Sclerosis

        10.3.7. Renal Cancer

        10.3.8. Wet Age-related Macular Degeneration

        10.3.9. Others

    10.4. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Targeted Therapeutics Market Attractiveness Analysis

        10.6.1. By Type 

        10.6.2. By Distribution Channel 

        10.6.3. By Country

11. Europe Targeted Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

        11.2.1. Monoclonal Antibodies

            11.2.1.1. Angiogenesis Inhibitors

            11.2.1.2. HER-2 Targeted Agents

            11.2.1.3. Anti-CD20 Monoclonal Antibodies

        11.2.2. Small Molecule

            11.2.2.1. Tyrosine Kinase Inhibitors

            11.2.2.2. mTOR Inhibitors

            11.2.2.3. PARP Inhibitors

    11.3. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031

        11.3.1. Breast Cancer

        11.3.2. Colorectal Cancer

        11.3.3. Leukemia

        11.3.4. Lung Cancer

        11.3.5. Lymphoma

        11.3.6. Multiple Sclerosis

        11.3.7. Renal Cancer

        11.3.8. Wet Age-related Macular Degeneration

        11.3.9. Others

    11.4. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe 

    11.6. Europe Targeted Therapeutics Market Attractiveness Analysis

        11.6.1. By Type  

        11.6.2. By Distribution Channel 

        11.6.3. By Country/Sub-region

12. Asia Pacific Targeted Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

        12.2.1. Monoclonal Antibodies

            12.2.1.1. Angiogenesis Inhibitors

            12.2.1.2. HER-2 Targeted Agents

            12.2.1.3. Anti-CD20 Monoclonal Antibodies

        12.2.2. Small Molecule

            12.2.2.1. Tyrosine Kinase Inhibitors

            12.2.2.2. mTOR Inhibitors

            12.2.2.3. PARP Inhibitors

    12.3. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031

        12.3.1. Breast Cancer

        12.3.2. Colorectal Cancer

        12.3.3. Leukemia

        12.3.4. Lung Cancer

        12.3.5. Lymphoma

        12.3.6. Multiple Sclerosis

        12.3.7. Renal Cancer

        12.3.8. Wet Age-related Macular Degeneration

        12.3.9. Others

    12.4. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. India

        12.5.3. Japan

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Targeted Therapeutics Market Attractiveness Analysis

        12.6.1. By Type 

        12.6.2. By Distribution Channel 

        12.6.3. By Country/Sub-region

13. Latin America Targeted Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

        13.2.1. Monoclonal Antibodies

            13.2.1.1. Angiogenesis Inhibitors

            13.2.1.2. HER-2 Targeted Agents

            13.2.1.3. Anti-CD20 Monoclonal Antibodies

        13.2.2. Small Molecule

            13.2.2.1. Tyrosine Kinase Inhibitors

            13.2.2.2. mTOR Inhibitors

            13.2.2.3. PARP Inhibitors

    13.3. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031

        13.3.1. Breast Cancer

        13.3.2. Colorectal Cancer

        13.3.3. Leukemia

        13.3.4. Lung Cancer

        13.3.5. Lymphoma

        13.3.6. Multiple Sclerosis

        13.3.7. Renal Cancer

        13.3.8. Wet Age-related Macular Degeneration

        13.3.9. Others

    13.4. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Targeted Therapeutics Market Attractiveness Analysis

        13.6.1. By Type 

        13.6.2. By Distribution Channel 

        13.6.3. By Country/Sub-region

14. Middle East & Africa Targeted Therapeutics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

        14.2.1. Monoclonal Antibodies

            14.2.1.1. Angiogenesis Inhibitors

            14.2.1.2. HER-2 Targeted Agents

            14.2.1.3. Anti-CD20 Monoclonal Antibodies

        14.2.2. Small Molecule

            14.2.2.1. Tyrosine Kinase Inhibitors

            14.2.2.2. mTOR Inhibitors

            14.2.2.3. PARP Inhibitors

    14.3. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031

        14.3.1. Breast Cancer

        14.3.2. Colorectal Cancer

        14.3.3. Leukemia

        14.3.4. Lung Cancer

        14.3.5. Lymphoma

        14.3.6. Multiple Sclerosis

        14.3.7. Renal Cancer

        14.3.8. Wet Age-related Macular Degeneration

        14.3.9. Others

    14.4. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis

        14.6.1. By Type 

        14.6.2. By Distribution Channel 

        14.6.3. By Country/Sub-region

15. Competitive Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Company Profiles

        15.2.1. Sanofi

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Financial Overview

            15.2.1.3. Product Portfolio

            15.2.1.4. Strategic Overview

            15.2.1.5. SWOT Analysis

        15.2.2. GlaxoSmithKline plc

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Financial Overview

            15.2.2.3. Product Portfolio

            15.2.2.4. Strategic Overview

            15.2.2.5. SWOT Analysis

        15.2.3. Takeda Pharmaceutical Company Limited

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Financial Overview

            15.2.3.3. Product Portfolio

            15.2.3.4. Strategic Overview

            15.2.3.5. SWOT Analysis

        15.2.4. Merck & Co., Inc.

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Financial Overview

            15.2.4.3. Product Portfolio

            15.2.4.4. Strategic Overview

            15.2.4.5. SWOT Analysis

        15.2.5. Novartis AG 

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Financial Overview

            15.2.5.3. Product Portfolio

            15.2.5.4. Strategic Overview

            15.2.5.5. SWOT Analysis

        15.2.6. Merck KGaA

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Financial Overview

            15.2.6.3. Product Portfolio

            15.2.6.4. Strategic Overview

            15.2.6.5. SWOT Analysis

        15.2.7. Pfizer Inc.

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Financial Overview

            15.2.7.3. Product Portfolio

            15.2.7.4. Strategic Overview

            15.2.7.5. SWOT Analysis

        15.2.8. F. Hoffmann-La Roche Ltd.

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Financial Overview

            15.2.8.3. Product Portfolio

            15.2.8.4. Strategic Overview

            15.2.8.5. SWOT Analysis

        15.2.9. AstraZeneca

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Financial Overview

            15.2.9.3. Product Portfolio

            15.2.9.4. Strategic Overview

            15.2.9.5. SWOT Analysis

        15.2.10. Seagen, Inc.

            15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.10.2. Financial Overview

            15.2.10.3. Product Portfolio

            15.2.10.4. Strategic Overview

            15.2.10.5. SWOT Analysis

        15.2.11. Bayer AG

            15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.11.2. Financial Overview

            15.2.11.3. Product Portfolio

            15.2.11.4. Strategic Overview

            15.2.11.5. SWOT Analysis

        15.2.12. Amgen, Inc.

            15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.12.2. Financial Overview

            15.2.12.3. Product Portfolio

            15.2.12.4. Strategic Overview

            15.2.12.5. SWOT Analysis

        15.2.13. Bristol-Myers Squibb Company

            15.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.13.2. Financial Overview

            15.2.13.3. Product Portfolio

            15.2.13.4. Strategic Overview

            15.2.13.5. SWOT Analysis

List of Tables

Table 01: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 02: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017-2031

Table 03: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017-2031

Table 04: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 05: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 06: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 08: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 09: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031

Table 10: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule , 2017–2031

Table 11: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 12: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 15: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 16: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 17: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 18: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 19: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 21: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031

Table 22: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017–2031

Table 23: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 25: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 27: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031

Table 28: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017–2031

Table 29: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 30: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 31: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 32: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 33: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031

Table 34: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017–2031

Table 35: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 36: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Targeted Therapeutics Market Value Share, by Application, 2020

Figure 03: Global Targeted Therapeutics Market Value Share, by Distribution Channel, 2020

Figure 04: Global Targeted Therapeutics Market Value Share, by Type, 2020

Figure 05: Global Targeted Therapeutics Market Value Share, by Region, 2020

Figure 07: Global Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031

Figure 06: Global Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031

Figure 08: Global Targeted Therapeutics Market Value (US$ Mn), by Monoclonal Antibodies, 2017-2031

Figure 09: Global Targeted Therapeutics Market Value (US$ Mn), by Small Molecule, 2017-2031

Figure 10: Global Targeted Therapeutics Market Value (US$ Mn), by Angiogenesis Inhibitors, 2017-2031

Figure 11: Global Targeted Therapeutics Market Value (US$ Mn), by HER-2 Targeted Agents, 2017-2031

Figure 12: Global Targeted Therapeutics Market Value (US$ Mn), by Anti-CD20 Monoclonal Antibodies, 2017-2031

Figure 13: Global Targeted Therapeutics Market Value (US$ Mn), by Angiogenesis Inhibitors, 2017-2031

Figure 14: Global Targeted Therapeutics Market Value (US$ Mn), by mTOR Inhibitors, 2017-2031

Figure 15: Global Targeted Therapeutics Market Value (US$ Mn), by PARP Inhibitors, 2017-2031

Figure 17: Global Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031

Figure 16: Global Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031

Figure 18: Global Targeted Therapeutics Market Value (US$ Mn), by Breast Cancer, 2017-2031

Figure 19: Global Targeted Therapeutics Market Value (US$ Mn), by Colorectal Cancer, 2017-2031

Figure 20: Global Targeted Therapeutics Market Value (US$ Mn), by Leukemia, 2017-2031

Figure 21: Global Targeted Therapeutics Market Value (US$ Mn), by Lung Cancer, 2017-2031

Figure 22: Global Targeted Therapeutics Market Value (US$ Mn), by Lymphoma, 2017-2031

Figure 23: Global Targeted Therapeutics Market Value (US$ Mn), by Multiple Sclerosis, 2017-2031

Figure 24: Global Targeted Therapeutics Market Value (US$ Mn), by Renal Cancer, 2017-2031

Figure 25: Global Targeted Therapeutics Market Value (US$ Mn), by Wet Age-related Macular Degeneration, 2017-2031

Figure 26: Global Targeted Therapeutics Market Value (US$ Mn), by Others, 2017-2031

Figure 28: Global Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 27: Global Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 29: Global Targeted Therapeutics Market Value (US$ Mn), by Hospital Pharmacies, 2017-2031

Figure 30: Global Targeted Therapeutics Market Value (US$ Mn), by Retail Pharmacies, 2017-2031

Figure 31: Global Targeted Therapeutics Market Value (US$ Mn), by Online Pharmacies, 2017-2031

Figure 32: Global Targeted Therapeutics Market Value Share Analysis, by Region, 2020 and 2031

Figure 33: Global Targeted Therapeutics Market Attractiveness Analysis, by Region, 2021–2031

Figure 34: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 35: North America Targeted Therapeutics Market Value Share Analysis, by Country, 2020 and 2031

Figure 36: North America Targeted Therapeutics Market Attractiveness Analysis, by Country, 2021–2031

Figure 37: North America Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031

Figure 38: North America Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031

Figure 39: North America Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031

Figure 40: North America Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031

Figure 41: North America Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 42: North America Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 43: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 44: Europe Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2030

Figure 45: Europe Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021–2030

Figure 46: Europe Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031

Figure 47: Europe Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031

Figure 48: Europe Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031

Figure 49: Europe Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031

Figure 50: Europe Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 51: Europe Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 52: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 53: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2030

Figure 54: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021–2030

Figure 55: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031

Figure 56: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031

Figure 57: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031

Figure 58: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031

Figure 59: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 60: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 61: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 62: Latin America Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2030

Figure 63: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021–2030

Figure 64: Latin America Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031

Figure 65: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031

Figure 66: Latin America Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031

Figure 67: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031

Figure 68: Latin America Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 69: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 70: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 71: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2030

Figure 72: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021–2030

Figure 73: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031

Figure 74: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031

Figure 76: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031

Figure 75: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031

Figure 77: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 78: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Targeted Therapeutics Market